These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37079860)

  • 1. Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.
    King DA; Smith AR; Pineda G; Nakano M; Michelini F; Goedegebuure SP; Thyparambil S; Liao WL; McCormick A; Ju J; Cioffi M; Zhang X; Hundal J; Griffith M; Grandori C; Pollastro M; Rosati R; Margossian A; Chatterjee P; Ainge T; Flory M; Ocampo P; Chen LM; Poultsides GA; Baron AD; Chang DT; Herman JM; Gillanders WE; Park H; Hoos WA; Nichols M; Fisher GA; Kuo CJ
    JCO Precis Oncol; 2023 Apr; 7():e2100489. PubMed ID: 37079860
    [No Abstract]   [Full Text] [Related]  

  • 2. Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma.
    Weinberg BA; Yabar CS; Brody JR; Pishvaian MJ
    Oncology (Williston Park); 2015 Nov; 29(11):809-20, 886. PubMed ID: 26573060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
    Ruess DA; Görgülü K; Wörmann SM; Algül H
    Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
    Pazderová N; Urbán V; Makovník M; Macák D; Janega P; Chovanec M; Rejleková K; Mardiak J; Mego M
    Klin Onkol; 2020; 33(3):220-225. PubMed ID: 32683879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
    Dancer J; Takei H; Ro JY; Lowery-Nordberg M
    Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.
    Harder J; Ihorst G; Heinemann V; Hofheinz R; Moehler M; Buechler P; Kloeppel G; Röcken C; Bitzer M; Boeck S; Endlicher E; Reinacher-Schick A; Schmoor C; Geissler M
    Br J Cancer; 2012 Mar; 106(6):1033-8. PubMed ID: 22374460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.
    Sonnenblick A; Kadouri L; Appelbaum L; Peretz T; Sagi M; Goldberg Y; Hubert A
    Cancer Biol Ther; 2011 Aug; 12(3):165-8. PubMed ID: 21613821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles.
    Grapa CM; Mocan T; Gonciar D; Zdrehus C; Mosteanu O; Pop T; Mocan L
    Int J Nanomedicine; 2019; 14():9693-9706. PubMed ID: 31849462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
    Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
    Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-family gene amplification and expression in resected pancreatic cancer.
    te Velde EA; Franke AC; van Hillegersberg R; Elshof SM; de Weger RW; Borel Rinkes IH; van Diest PJ
    Eur J Surg Oncol; 2009 Oct; 35(10):1098-104. PubMed ID: 19304440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
    Pishvaian MJ; Brody JR
    Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of c-erbB-2 oncogene protein, epidermal growth factor receptor, and TGF-beta1 in human pancreatic ductal adenocarcinoma.
    Zhang L; Yuan SZ
    Hepatobiliary Pancreat Dis Int; 2002 Nov; 1(4):620-3. PubMed ID: 14607699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
    Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
    Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
    Das S; Cardin D
    Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of c-erbB-2 in human pancreatic adenocarcinomas.
    Williams TM; Weiner DB; Greene MI; Maguire HC
    Pathobiology; 1991; 59(1):46-52. PubMed ID: 1675057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu and topoisomerase-II-alpha expression and genic amplification in pancreatic adenocarcinoma.
    Baiocchi GL; Villanacci V; Rossi E; Gheza F; Portolani N; Giulini SM
    Dig Dis Sci; 2009 Sep; 54(9):2049-51. PubMed ID: 19582575
    [No Abstract]   [Full Text] [Related]  

  • 17. The treatment of advanced pancreatic cancer: current evidence and future challenges.
    Moore MJ
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii304-8. PubMed ID: 18790971
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review.
    Patel GK; Perry JB; Abdul-Rahim O; Frankel AE; Cameron D; Taylor W; Rocconi RP; Abushahin L; Nelson C; Singh AP; Khushman M
    J Cancer Res Ther; 2020; 16(4):950-954. PubMed ID: 32930150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
    Bekaii-Saab T
    Clin Adv Hematol Oncol; 2018 Sep; 16 Suppl 17(9):5-7. PubMed ID: 30807560
    [No Abstract]   [Full Text] [Related]  

  • 20. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
    Botta GP; Kato S; Patel H; Fanta P; Lee S; Okamura R; Kurzrock R
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34375311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.